|
**Overview**: Anti-Neutrophil Cytoplasmic Antibody IFA Panel**Introduction**: The Anti-Neutrophil Cytoplasmic Antibody IFA Panel is a diagnostic tool designed to screen for ANCA-related vasculitis using serum samples. In India, ANCA-associated vasculitis (AAV) is increasingly recognized (prevalence ~10-20 per million), with c-ANCA/PR3 and p-ANCA/MPO patterns common in granulomatosis with polyangiitis and microscopic polyangiitis. Presents with renal failure, pulmonary hemorrhage, sinusitis, or skin lesions. High morbidity from underdiagnosis in rural areas, limited rheumatology access, and overlap with infections/TB. Per immunology practices aligned with ICMR guidelines, the test employs immunofluorescence for pattern detection over 1-2 days with high sensitivity/specificity, valuable for initial vasculitis screening. This diagnostic falls under autoimmune screening and targets individuals with suspected vasculitis, addressing accurate detection to guide immunosuppressive therapy. With morbidity elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing organ damage. Its serum-based approach ensures reliable detection.**Other Names**: ANCA IFA Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Established as IFA standard; in India, prominence with rising vasculitis awareness.**Purpose**: The test screens for 3 parameters including c-ANCA to guide vasculitis assessment, identify patterns, inform further testing.**Test Parameters**: 1. c-ANCA, 2. p-ANCA, 3. Atypical ANCA.**Pretest Condition**: No fasting required; patients should report renal issues, pulmonary symptoms, sinusitis, or skin lesions.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on renal function, pulmonary symptoms, sinusitis, skin lesions, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated vasculitis including organ failure, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunofluorescence by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible ANCA vasculitis, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Rheumatologists or nephrologists should be consulted for case management, treatment planning.**Additional Supporting Tests**: ANCA ELISA or biopsy for confirmation.**Test Limitations**: The test may produce false negatives in limited disease or false positives in infections; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Vasculitis Studies India 2023. |
